Bacterial Polyester Inclusions Engineered to Display Vaccine Candidate Antigens for Use As a Novel Class of Safe and Efficient Vaccine Delivery Agents

Overview

Journal Appl Environ Microbiol

Specialties Environmental Health
Microbiology

Date 2009 Oct 20

PMID 19837843

Citations 23

Authors

Natalie A Parlane

D Neil Wedlock

Bryce M Buddle

Bernd H A Rehm

Affiliations

Soon will be listed here.

Abstract

Bioengineered bacterial polyester inclusions have the potential to be used as a vaccine delivery system. The biopolyester beads were engineered to display a fusion protein of the polyester synthase PhaC and the two key antigens involved in immune response to the infectious agent that causes tuberculosis, Mycobacterium tuberculosis, notably antigen 85A (Ag85A) and the 6-kDa early secreted antigenic target (ESAT-6) from Mycobacterium tuberculosis. Polyester beads displaying the respective fusion protein at a high density were successfully produced (henceforth called Ag85A-ESAT-6 beads) by recombinant Escherichia coli. The ability of the Ag85A-ESAT-6 beads to enhance mouse immunity to the displayed antigens was investigated. The beads were not toxic to the animals, as determined by weight gain and absence of lesions at the inoculation site in immunized animals. In vivo injection of the Ag85A-ESAT-6 beads in mice induced significant humoral and cell-mediated immune responses to both Ag85A and ESAT-6. Vaccination with Ag85A-ESAT-6 beads was efficient at stimulating immunity on their own, and this ability was enhanced by administration of the beads in an oil-in-water emulsion. In addition, vaccination with the Ag85A-ESAT-6 beads induced significantly stronger humoral and cell-mediated immune responses than vaccination with an equivalent dose of the fusion protein Ag85A-ESAT-6 alone. The immune response induced by the beads was of a mixed Th1/Th2 nature, as assessed from the induction of the cytokine gamma interferon (Th1 immune response) and increased levels of immunoglobulin G1 (Th2 immune response). Hence, engineered biopolyester beads displaying foreign antigens represent a new class of versatile, safe, and biocompatible vaccines.

Citing Articles

Exploiting Polyhydroxyalkanoates for Biomedical Applications.

Kalia V, Patel S, Lee J Polymers (Basel). 2023; 15(8).

PMID: 37112084 PMC: 10144186. DOI: 10.3390/polym15081937.

A -Derived Particulate Vaccine Protects against Infection.

Gonzaga Z, Merakou C, DiGiandomenico A, Priebe G, Rehm B Vaccines (Basel). 2021; 9(7).

PMID: 34358220 PMC: 8309987. DOI: 10.3390/vaccines9070803.

Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation.

Younis S, Barnier-Quer C, Heuking S, Sommandas V, Brunner L, Vd Werff N BMC Immunol. 2018; 19(1):6.

PMID: 29386070 PMC: 5793412. DOI: 10.1186/s12865-018-0245-0.

Bioengineered polyester beads co-displaying protein and carbohydrate-based antigens induce protective immunity against bacterial infection.

Gonzalez-Miro M, Rodriguez-Noda L, Farinas-Medina M, Cedre-Marrero B, Madariaga-Zarza S, Zayas-Vignier C Sci Rep. 2018; 8(1):1888.

PMID: 29382864 PMC: 5789850. DOI: 10.1038/s41598-018-20205-7.

Biomedical Applications of Polyhydroxyalkanoates.

Ray S, Kalia V Indian J Microbiol. 2017; 57(3):261-269.

PMID: 28904409 PMC: 5574769. DOI: 10.1007/s12088-017-0651-7.

References

Yuan W, Jia Y, Tian J, Snell K, Muh U, Sinskey A . Class I and III polyhydroxyalkanoate synthases from Ralstonia eutropha and Allochromatium vinosum: characterization and substrate specificity studies. Arch Biochem Biophys. 2001; 394(1):87-98. DOI: 10.1006/abbi.2001.2522. View

Ratliff T, Wiker H, HARBOE M, Bennedsen J, Rook G . Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG. Infect Immun. 1988; 56(12):3046-51. PMC: 259698. DOI: 10.1128/iai.56.12.3046-3051.1988. View

Giri P, Verma I, Khuller G . Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration. FEMS Immunol Med Microbiol. 2006; 47(2):233-41. DOI: 10.1111/j.1574-695X.2006.00087.x. View

Pollock J, Andersen P . Predominant recognition of the ESAT-6 protein in the first phase of interferon with Mycobacterium bovis in cattle. Infect Immun. 1997; 65(7):2587-92. PMC: 175366. DOI: 10.1128/iai.65.7.2587-2592.1997. View

Ganta S, Devalapally H, Shahiwala A, Amiji M . A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release. 2008; 126(3):187-204. DOI: 10.1016/j.jconrel.2007.12.017. View

Brockelbank J, Peters V, Rehm B . Recombinant Escherichia coli strain produces a ZZ domain displaying biopolyester granules suitable for immunoglobulin G purification. Appl Environ Microbiol. 2006; 72(11):7394-7. PMC: 1636211. DOI: 10.1128/AEM.01014-06. View

Atwood J, Rehm B . Protein engineering towards biotechnological production of bifunctional polyester beads. Biotechnol Lett. 2008; 31(1):131-7. DOI: 10.1007/s10529-008-9836-9. View

HARBOE M, Oettinger T, Wiker H, Rosenkrands I, Andersen P . Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun. 1996; 64(1):16-22. PMC: 173721. DOI: 10.1128/iai.64.1.16-22.1996. View

Jahns A, Haverkamp R, Rehm B . Multifunctional inorganic-binding beads self-assembled inside engineered bacteria. Bioconjug Chem. 2008; 19(10):2072-80. DOI: 10.1021/bc8001979. View

10.

Huygen K, Content J, Denis O, Montgomery D, Yawman A, Deck R . Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med. 1996; 2(8):893-8. DOI: 10.1038/nm0896-893. View

11.

Corbett E, Charalambous S, Fielding K, Clayton T, Hayes R, De Cock K . Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB. J Infect Dis. 2003; 188(8):1156-63. DOI: 10.1086/378519. View

12.

Kaufmann S . Rational design of novel antibacterial vaccines with an emphasis on tuberculosis. Scand J Infect Dis. 2008; 40(8):595-600. DOI: 10.1080/00365540802032759. View

13.

Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy H . Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis. 1999; 179(3):637-45. DOI: 10.1086/314640. View

14.

Singh M, Chakrapani A, OHagan D . Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines. 2007; 6(5):797-808. DOI: 10.1586/14760584.6.5.797. View

15.

Peters V, Rehm B . Protein engineering of streptavidin for in vivo assembly of streptavidin beads. J Biotechnol. 2008; 134(3-4):266-74. DOI: 10.1016/j.jbiotec.2008.02.006. View

16.

Brandt L, Oettinger T, Holm A, Andersen A, Andersen P . Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol. 1996; 157(8):3527-33. View

17.

Kumar H, Kawai T, Akira S . Toll-like receptors and innate immunity. Biochem Biophys Res Commun. 2009; 388(4):621-5. DOI: 10.1016/j.bbrc.2009.08.062. View

18.

Liang M, Davies N, Blanchfield J, Toth I . Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr Drug Deliv. 2006; 3(4):379-88. DOI: 10.2174/156720106778559029. View

19.

Peters V, Becher D, Rehm B . The inherent property of polyhydroxyalkanoate synthase to form spherical PHA granules at the cell poles: the core region is required for polar localization. J Biotechnol. 2007; 132(3):238-45. DOI: 10.1016/j.jbiotec.2007.03.001. View

20.

Peters V, Rehm B . In vivo enzyme immobilization by use of engineered polyhydroxyalkanoate synthase. Appl Environ Microbiol. 2006; 72(3):1777-83. PMC: 1393242. DOI: 10.1128/AEM.72.3.1777-1783.2006. View